Table 2 Clinical parameters, metabolic factors and adipose tissue compartment changes from baseline after 26 weeks of treatment in the intention-to-treat analysis
Characteristic | Mean ± SD change from baseline to 26 weeks | Mean [95% CI] changes from baseline (liraglutide vs placebo) | P value | |
|---|---|---|---|---|
Liraglutide (n = 22) | Placebo (n = 25) | |||
Clinical parameters | ||||
 Body weight (kg) | − 3.9 ± 3.6 | − 0.6 ± 2.2 | − 3.5 [− 5.3, − 1.8] | < 0.001 |
 BMI (kg/m2) | − 1.5 ± 1.4 | − 0.2 ± 0.8 | − 1.4 [− 2.0, − 0.7] | < 0.001 |
 Waist circumference (cm) | − 5 ± 4 | 0 ± 4 | − 5 [− 8, − 2] | < 0.001 |
 Hip circumference (cm) | − 4 ± 5 | − 2 ± 3 | − 2 [− 5, 0] | 0.067 |
 Waist-hip ratio | − 0.01 ± 0.04 | 0.02 ± 0.05 | − 0.01 [− 0.04, 0.01] | 0.312 |
 Lean body mass (kg) | − 2.3 ± 2.3 | 0.4 ± 2.9 | − 2.7 [− 4.3, − 1.1] | 0.001 |
 Lean body mass (%) | 0.2 ± 1.7 | 0.8 ± 2.7 | − 0.6 [− 1.9, 0.8] | 0.403 |
Metabolic factors | ||||
 HbA1c (mmol/mol) | − 8.5 ± 11.2 | − 6.8 ± 9.3 | − 4.0 [− 9.7, 1.6] | 0.156 |
 HbA1c (%) | − 0.8 ± 1.0 | − 0.6 ± 0.8 | − 0.4 [− 0.9, 0.1] | 0.156 |
 Total cholesterol (mmol/L) | 0.24 ± 1.09 | − 0.42 ± 0.82 | 0.52 [− 0.05, 1.09] | 0.073 |
 HDL-cholesterol (mmol/L) | − 0.04 ± 0.12 | − 0.05 ± 0.12 | 0.02 [− 0.05, 0.09] | 0.657 |
 LDL-cholesterol (mmol/L) | 0.15 ± 0.74 | − 0.14 ± 0.74 | 0.22 [− 0.20, 0.63] | 0.296 |
 Triglycerides (mmol/L) | 0.28 ± 1.25 | − 0.38 ± 1.30 | 0.40 [− 0.24, 1.04] | 0.214 |
Adipose tissue compartments | ||||
 Subcutaneous AT (cm2) | − 24 ± 37 | − 10 ± 37 | − 15 [− 37, 6] | 0.158 |
 Visceral AT (cm2) | − 20 ± 29 | − 2 ± 17 | − 13 [− 27, 1] | 0.074 |
 Epicardial AT (cm2) | 0 ± 2 | 1 ± 1 | − 1 [− 2, 0] | 0.232 |
 Paracardial AT (cm2) | − 1 ± 3 | 0 ± 3 | − 1 [− 2, 1] | 0.494 |
 Hepatic TGC (%) | − 1.2 ± 4.1 | − 3.3 ± 5.4 | 0.4 [− 1.9, 2.8] | 0.704 |
 Myocardial TGC (%) | 0.1 ± 0.5 | − 0.1 ± 0.6 | 0.2 [− 0.1, 0.5] | 0.157 |